索拉非尼作为挽救性治疗在难治复发性FLT3突变阳性急性
髓系白血病中的临床应用研究
张钰;宣丽;范志平;黄芬;江千里;许娜;高雅;孙竞;刘启发
【期刊名称】《中华血液学杂志》 【年(卷),期】2016(037)004
【摘要】Objective To analyze the effect of sorafenib as salvage therapy used before and/or after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in refractory relapsed FLT3-positive acute myeloid leukemia (AML).Methods A total of 16 patients with refractory relapsed FLT3-positive AML,including 10 refractory relapsed pre-transplantation and 6 relapsed after allo-HSCT,were enrolled in this retrospective study.Sorafenib treatment protocols included sorafenib in combination with chemotherapy inducing remission,and sorafenib monotherapy as mauntenance treatment after complete remission (CR).Results Thirteen of the 16 patients achieved CR after one or two courses of induction therapy,including 7 refractory relapsed pre-transplantation and 6 relapsed after allo-HSCT.With a median follow up of 472 (range,59-1 569) days post-transplantation,12 patients survived and 4 died.Causes of death included leukemia relapse (n=3) and acute graft-versus-host disease (n=l).The 2-year overall and disease-free survival post-transplantation of the 16 patients were (75.0± 10.8)％ and (50.5± 13.7)％ respectively.The main side effect of sorafenib was the
索拉非尼作为挽救性治疗在难治复发性FLT3突变阳性急性髓系白血病
